Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.

被引：0
|
作者：
Meng, Xiangrui
Yang, Xiuli
Hong, Yong-Gui
Zhang, Zhiye
Xia, Jin
Chen, Yunfang
Wu, Tao
Shan, Zheng-Zheng
Fan, Qingxia
Wang, Feng
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] First Affiliated Hosp, Nanyang Med Coll, Nanyang, Peoples R China
[3] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China
[5] Zhumadian Cent Hosp, Zhumadian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16035
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
    Wang, Zhi-ming
    Zhuang, Rong-yuan
    Guo, Xi
    Zhang, Chen-lu
    You, Yang
    Chen, Li-sha
    Liu, Wen-shuai
    Zhang, Yong
    Luo, Rong-kui
    Hou, Ying-yong
    Lu, Wei-qi
    Zhou, Yu-hong
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5290 - 5296
  • [32] Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial
    Jia, Yong-Xu
    Chang, Zhiwei
    Zhong, Ya-Li
    Cui, Donghai
    Han, Hui-Qiong
    Gao, Ya-Ping
    He, Jian
    Liu, Xiao-Lei
    Yan, Jie
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 444 - 444
  • [33] Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial
    Huang, W.
    Han, D.
    Li, B.
    Dong, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S902 - S902
  • [34] Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.
    Shen, Lin
    Yu, Xianjun
    Lu, Ming
    Zhang, Xing
    Cheng, Ying
    Zhang, Yanqiao
    Li, Zhiping
    Xu, Jianming
    Weng, Desheng
    Wu, Chunjiao
    Ma, Yue
    Cheng, Ke
    Wang, Wenquan
    Gao, Heli
    Li, Yi
    Zhou, Jinghong
    Shi, Haiyan
    Tan, Panfeng
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Wang Junsheng
    Wu Tao
    Hong Yonggui
    Meng Xiangrui
    Ren Zhonghai
    Guo Yanzhen
    Yang Xiuli
    Shi Pei
    Yang Jiamei
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [36] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
    Gong, Lei
    Yang, Yueyang
    Zhang, Hongdian
    Qiao, Yufeng
    Wang, Haitong
    Ren, Peng
    Tang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
    Jin, Y.
    Yu, X.
    Fan, Y.
    He, X. Q.
    Lin, C.
    Hong, W.
    Gu, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1656 - S1657
  • [38] Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS)
    Jiang, Youhua
    Qiu, Guoqin
    Li, Jianqiang
    Wang, Jiangfeng
    Wang, Changchun
    Wu, Jie
    Cheng, Lei
    Zheng, Yuanda
    Ruan, Rongwei
    Song, Ge
    Ye, Xuemei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] CAMRELIZUMAB COMBINED WITH PACLITAXEL AND NEDAPLATIN IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM, EXPLORATORY RESEARCH
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A437 - A437
12345